Axiom Real-Time Metrics announced its engagement with Emergent BioSolutions.
“Axiom is passionate about giving sponsors solutions that harness the power of their data to drive clinical research. We deliver technology and services to innovative life sciences organizations to provide them with the information that they need – in real-time – so that they are empowered with the robust and timely insights which are required for compliance, effective trial conduct, and successful drug development,” Andrew Schachter, Founder & CEO of Axiom, said. “We are very pleased to build this relationship with Emergent and potentially be a long-term partner in meeting their evolving needs as they develop drugs that are critical to patient well-being and position them at the leading edge of infectious disease treatments.”
“We are delighted to have found a fully integrated clinical suite that will allow us to scale up seamlessly while optimizing our processes to capitalize on the unmatched potential offered by Axiom’s Fusion platform,” Paul-André de Lame, VP, Clinical Development at Emergent said.
“We are integral partners to our sponsors, driving clinical development success through the unique combination of thoughtful planning, best-in-class Fusion eClinical technology, and our Axiom team members who are passionately dedicated to their trials,” Meredith Frank-Molnia, Senior Director Clinical Management at Axiom, said.